Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Verinurad prolonged release HPMC · 1 trial · 1 indication
The AUCinf of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters
The AUClast of verinurad, allopurinol and oxypurinol were assessed in fasted condition as PK parameters
The Cmax of verinurad, allopurinol and oxypurinol were assessed in fasted state as PK parameters
| Arm | Type | Description |
|---|---|---|
| Treatment 1 | EXPERIMENTAL | Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fasted state on Day 1. |
| Treatment 2 | EXPERIMENTAL | Subjects will receive verinurad/allopurinol FDC capsule in fasted state on Day 1. |
| Treatment 3 | EXPERIMENTAL | Subjects will receive verinurad/allopurinol FDC capsule in fed state on Day 1. |
| Treatment 4 | EXPERIMENTAL | Subjects will receive verinurad prolonged release HPMC capsule and allopurinol tablet in fed state on Day 1. |
| Treatment 5 | EXPERIMENTAL | Subjects will receive verinurad prolonged release gelatin capsule in fasted state on Day 1. |
| Name | Type | Description |
|---|---|---|
| Verinurad prolonged release HPMC capsule | DRUG | Randomized subjects will receive oral dose of verinurad HPMC capsule. |
| Allopurinol Tablet | DRUG | Randomized subjects will receive oral dose of allopurinol tablet. |
| Verinurad/Allopurinol FDC Capsule | DRUG | Randomized subjects will receive oral dose of Verinurad/Allopurinol FDC capsule. |
| Verinurad prolonged release gelatin Capsule | DRUG | Randomized subjects will receive oral dose of Verinurad gelatin capsule. |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male and female subjects aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture. * Have a body mass index between 18 and 30 kg/m\^2 (...
Top 20 of 25 competitors
Verinurad prolonged release HPMC is an investigational small molecule being studied for chronic kidney disease. It is currently in Phase 1 clinical development. The drug is being evaluated in a clinical trial involving healthy subjects to assess drug availability of different formulations of verinurad and allopurinol.
Verinurad prolonged release HPMC is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this drug candidate for chronic kidney disease, with the drug currently in Phase 1 development.
Verinurad prolonged release HPMC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, which studied drug availability of different formulations of verinurad and allopurinol in healthy subjects.
Verinurad prolonged release HPMC has one completed clinical trial, NCT04550234, titled "A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol." This Phase 1 study enrolled 25 participants in Germany and evaluated the drug in healthy volunteers.
Verinurad prolonged release HPMC is a specific formulation of verinurad, using hydroxypropyl methylcellulose (HPMC) as a prolonged release matrix. The clinical trial NCT04550234 assessed four different formulations of verinurad and allopurinol, including this prolonged release version, to compare drug availability.